Hikal Limited — Investor Meet, 13-08-2025: Analysts/Institutional Investor Meet/Con. Call Updates

Hikal's Q1 FY26 revenue was Rs 380 Cr, with EBITDA at Rs 25 Cr (6.5% margin). Performance was impacted by Rs 50 Cr deferred Pharma shipments (expected in H2) and Crop Protection pricing pressure. US FDA issued OAI status for Bangalore (procedural; no data integrity); 75-80% corrective actions completed, full resolution by September-end. ANVISA/PMDA audits were successful. Management is confident of H2 recovery, reiterating FY26 Pharma growth (12-14%) and flat Crop Protection. Strategic focus on CDMO, Animal Health, and personal care through Panoli expansion continues for future growth.